Rulemaking Needed For Acetaminophen Skin-Reaction Label Warning – CHPA
This article was originally published in The Tan Sheet
Executive Summary
The Consumer Healthcare Products Association encourages FDA to conduct a rulemaking to require label changes for acetaminophen OTCs the agency is suggesting in a draft guidance. The trade group also asks for clarity in the order warnings are placed on product labels.
You may also be interested in...
Guidance On Acetaminophen Allergy Warning Trails Industry's Change
Final US guidance adds CHPA's suggestion for an example for a warning on labeling for products containing both acetaminophen and aspirin, needed to highlight where “Allergy Alert” and “Liver Warning” statements are on those products' labels.
Guidance On Acetaminophen Allergy Warning Trails Industry's Change
Final US guidance adds CHPA's suggestion for an example for a warning on labeling for products containing both acetaminophen and aspirin, needed to highlight where “Allergy Alert” and “Liver Warning” statements are on those products' labels.
Draft Guidance Drills Down With Details To Cut Pediatric Acetaminophen Overdose Risk
FDA suggests new and repeats previous recommendations to reduce the risk of pediatric overdose with acetaminophen products due either to unsupervised ingestion or therapeutic errors. The guidance includes greater detail on delivery devices and labeling information for pediatric acetaminophen OTCs.